LogicBio Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

LogicBio Therapeutics (Nasdaq:LOGC) announced key presentations at upcoming investor conferences. COO Kyle Chiang will participate in a fireside chat at the Barclay's Gene Editing and Gene Therapy Summit on November 16, 2020. CEO Frederic Chereau is set to present at the Jeffries Virtual London Healthcare Conference on November 19, 2020, and will also record a session for the Piper Sandler Virtual Healthcare Conference, available from November 30, 2020. The company focuses on advancing genetic medicine with its GeneRide technology, and has received FDA clearance for its first clinical trial of LB-001.

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery today announced senior member of management will be presenting at upcoming investor conferences

• COO Kyle Chiang will participate in fireside chat at the Barclay’s Gene Editing and Gene Therapy Summit on Monday November 16, 2020 at 8:15 AM ET
  
• CEO Frederic Chereau will present at the Jeffries Virtual London Healthcare Conference Genetic Medicines Conference on Thursday, November 19, 2020 at 7:20 AM, ET.
  

• CEO Frederic Chereau will record an on-demand presentation for the 32^nd annual Piper Sandler Virtual Healthcare Conference that will be made available to attendees of the conference beginning on November 30, 2020.
  

Links to all presentations will be available under the investors tab at www.logicbio.com upon their availability.

About LogicBio Therapeutics

LogicBio Therapeutics is dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms. LogicBio’s proprietary genome editing technology platform, GeneRide, enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. LogicBio has received FDA clearance for the first-in-human clinical trial of LB-001, a wholly owned genome editing program leveraging GeneRide for the treatment of methylmalonic acidemia. Patient enrollment is expected to begin in early 2021. In addition, LogicBio has a collaboration with Takeda to research and develop LB-301, an investigational therapy leveraging GeneRide for the treatment of the rare pediatric disease Crigler-Najjar syndrome.

LogicBio is also developing a Next Generation Capsid platform for use in gene editing and gene therapies. Data presented have shown that the capsids deliver highly efficient functional transduction of human hepatocytes with improved manufacturability with low levels of pre-existing neutralizing antibodies in human samples. Top-tier capsid candidates from this effort demonstrated significant improvements over benchmark AAVs currently in clinical development. LogicBio is developing these highly potent vectors for internal development candidates and potentially for business development collaborations.

Contact:

Matthias Jaffe
Chief Financial Officer
mjaffe@logicbio.com
(617) 245-0399

FAQ

What presentations will LogicBio Therapeutics have in November 2020?

LogicBio Therapeutics will have COO Kyle Chiang present at the Barclay's Gene Editing and Gene Therapy Summit on November 16, and CEO Frederic Chereau at the Jeffries Virtual London Healthcare Conference on November 19. Chereau will also record a session for the Piper Sandler conference, available from November 30.

What is GeneRide technology?

GeneRide is LogicBio's proprietary genome editing technology that enables the site-specific integration of therapeutic transgenes without nucleases, leveraging homologous recombination.

What is the significance of LB-001 for LogicBio?

LB-001 is LogicBio's first-in-human clinical trial program, aimed at treating methylmalonic acidemia, and FDA clearance has been received for this trial.

When is patient enrollment for LB-001 expected to begin?

Patient enrollment for LB-001 is expected to begin in early 2021.

What collaboration does LogicBio have with Takeda?

LogicBio is collaborating with Takeda to research and develop LB-301, an investigational therapy for the rare pediatric disease Crigler-Najjar syndrome.